Korean pharmaceutical company GC Green Cross has acquired a blood bank in the United States.
The company noted on the 11th that it will acquire the entire equity of ABO Holdings, a company based in California. ABO Holdings operates six blood banks in three regions: New Jersey, Utah, and California. It is also in the process of constructing two additional blood banks in Texas, which are expected to be operational by 2026, bringing the total to eight blood banks.
This is part of the strategy to expand the business of the blood product ‘Aliglo,’ which has been exported to the U.S. since July. The acquisition of blood banks has secured a stable supply of raw materials for blood product pharmaceuticals. A representative from Green Cross said, “Through this acquisition of blood banks, we have completed vertical integration from securing raw materials for plasma-derived products to production and sales,” adding, “We will use the blood bank acquisition as a stepping stone for a quantum leap to become a global top-tier blood product company.”
Aliglo is an immunoglobulin blood product that received item approval from the U.S. Food and Drug Administration (FDA) in December of last year. It is an intravenous treatment used for primary humoral immunodeficiency, also known as congenital immunodeficiency. This product is manufactured through the company's proprietary Cation Exchange Chromatography (CEX) method, which minimizes the detection of impurities such as blood coagulation factor (FXIa), providing superior safety compared to existing medications.